自引率: 暂无数据
被引量: 0
通过率: 暂无数据
审稿周期: 4.67
版面费用: 暂无数据
国人发稿量: 79
投稿须知/期刊简介:
BMC Complementary Medicine and Therapies is an open access journal publishing original peer-reviewed research articles on interventions and resources that complement or replace conventional therapies, with a specific emphasis on research that explores the biological mechanisms of action, as well as their efficacy, safety, costs, patterns of use and/or implementation. 该期刊2020年1月更名，旧名为：BMC Complementary and Alternative Medicine
-
Use of complementary and alternative medicine in patients with chronic liver diseases in Germany- a multicentric observational study.
被引量：- 发表：1970
-
Varieties of silence - a mixed-methods study exploring reasons and justifications for nondisclosure of the use of complementary therapies to physicians in Finland.
被引量：- 发表：1970
-
The effectiveness of phytosomal curcumin on clinical and laboratory parameters of patients with multiple trauma admitted to the intensive care unit: a double-blind randomized placebo-controlled trial.
被引量：- 发表：1970
-
Baicalin relieves complement alternative pathway activation-induced lung inflammation through inhibition of NF-κB pathway.
被引量：- 发表：1970
-
In vitro study on efficacy of SKF7(®), a Malaysian medicinal plant product against SARS-CoV-2.
In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilum extract (SKF7®) focusing on anti-SARS-CoV-2 and anti-inflammatory activities. Anti-SARS-CoV-2 potential of the SKF7® was evaluated in SARS-CoV-2-infected Vero E6 cells and SARS-CoV-2-infected A549 cells by cytopathic effect-based assay and RT-qPCR, respectively. Target based assays were performed on the SKF7® against the S1-ACE2 interaction and 3CL protease activities. Anti-inflammatory activity of the SKF7® was evaluated by nitric oxide inhibitory and TLR2/TLR4 receptor blocker assays. The SKF7® inhibited wild-type Wuhan (EC50 of 21.99 µg/mL) and omicron (EC50 of 16.29 µg/mL) SARS-CoV-2 infections in Vero-E6 cells. The SKF7® also inhibited the wild-type SARS-CoV-2 infection in A549 cells (EC50 value of 6.31 µg/mL). The SKF7® prominently inhibited 3CL protease activity. The SKF7® inhibited the LPS induced-TLR4 response with the EC50 of 16.19 µg/mL. In conclusion, our in vitro study highlighted anti-SARS-CoV-2 and anti-inflammatory potentials of the SKF7®. Future pre-clinical in vivo studies focusing on antiviral and immunomodulatory potentials of the SKF7® in affecting the COVID-19 pathogenesis are warranted.
被引量：- 发表：1970
